Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY ® (pertuzumab) 420 mg/14 mL injection for ...

Two Chinese technology firms involved in the development of pharmaceutical drugs have clinched partnership agreements in Southeast Asia and the Middle East, as the industry increasingly looks beyond ...

The therapy is designed to be used as a treatment for multiple myeloma. Credit: luchschenF/Shutterstock. · Pharmaceutical Technology · luchschenF/Shutterstock. The above button links to Coinbase.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

HENLIUS (02696.HK) announced that the marketing authorization application for its self-developed POHERDY?(pertuzumab) ...

LUND, SE / ACCESS Newswire / April 23, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Shanghai ...

Last week, Shanghai Henlius Biotech teed up for a $477 million IPO on the Hong Kong Stock Exchange. It fell a little short when it priced on Wednesday, ultimately bagging $410 million, but still made ...

With a Chinese approval of PD-1 inhibitor serplulimab in March, Fosun Pharma’s Shanghai Henlius Biotech officially kicked off its transformation into an innovative biopharma company. Now, riding a ...

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2 ...

"Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our ...